44 related articles for article (PubMed ID: 22451182)
1. Efficacy and safety of pioglitazone in type 2 diabetes mellitus: a postmarketing observational study.
Nafrialdi
Acta Med Indones; 2012 Jan; 44(1):28-34. PubMed ID: 22451182
[TBL] [Abstract][Full Text] [Related]
2. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
Miyazaki Y; DeFronzo RA
Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
[TBL] [Abstract][Full Text] [Related]
3. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Gravina A; Fogari E; Maffioli P; Cicero AF
Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
[TBL] [Abstract][Full Text] [Related]
4. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
[TBL] [Abstract][Full Text] [Related]
5. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
Wenying Y; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shah S; Shestakova M; Ligthelm R; Valensi P;
Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
[TBL] [Abstract][Full Text] [Related]
6. Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study.
Davidson JA; Perez A; Zhang J;
Diabetes Obes Metab; 2006 Mar; 8(2):164-74. PubMed ID: 16448520
[TBL] [Abstract][Full Text] [Related]
7. Successful switch from insulin therapy to treatment with pioglitazone in type 2 diabetes patients with residual beta-cell function: results from the PioSwitch study.
Hohberg C; Pfützner A; Forst T; Lübben G; Karagiannis E; Borchert M; Schöndorf T
Diabetes Obes Metab; 2009 May; 11(5):464-71. PubMed ID: 19422402
[TBL] [Abstract][Full Text] [Related]
8. Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome.
Berria R; Gastaldelli A; Lucidi S; Belfort R; De Filippis E; Easton C; Brytzki R; Cusi K; Jovanovic L; DeFronzo R
Clin Pharmacol Ther; 2006 Aug; 80(2):105-14. PubMed ID: 16890572
[TBL] [Abstract][Full Text] [Related]
9. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial.
Charbonnel BH; Matthews DR; Schernthaner G; Hanefeld M; Brunetti P;
Diabet Med; 2005 Apr; 22(4):399-405. PubMed ID: 15787663
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.
Rosenstock J; Kim SW; Baron MA; Camisasca RP; Cressier F; Couturier A; Dejager S
Diabetes Obes Metab; 2007 Mar; 9(2):175-85. PubMed ID: 17300593
[TBL] [Abstract][Full Text] [Related]
11. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus.
Sharma PK; Bhansali A; Sialy R; Malhotra S; Pandhi P
Clin Endocrinol (Oxf); 2006 Dec; 65(6):722-8. PubMed ID: 17121522
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy.
Rosenstock J; Einhorn D; Hershon K; Glazer NB; Yu S;
Int J Clin Pract; 2002 May; 56(4):251-7. PubMed ID: 12074206
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes.
Pérez-Monteverde A; Seck T; Xu L; Lee MA; Sisk CM; Williams-Herman DE; Engel SS; Kaufman KD; Goldstein BJ
Int J Clin Pract; 2011 Sep; 65(9):930-8. PubMed ID: 21849007
[TBL] [Abstract][Full Text] [Related]
14. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome.
Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Piccinni MN; Fogari E; Salvadeo S; Ciccarelli L; Fogari R
Diabetes Res Clin Pract; 2005 Jul; 69(1):5-13. PubMed ID: 15955382
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
[TBL] [Abstract][Full Text] [Related]
16. Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load.
Derosa G; Cicero AF; Fogari E; D'Angelo A; Bianchi L; Maffioli P
Horm Metab Res; 2011 Jun; 43(7):505-12. PubMed ID: 21590648
[TBL] [Abstract][Full Text] [Related]
17. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes.
Tan MH; Johns D; Strand J; Halse J; Madsbad S; Eriksson JW; Clausen J; Konkoy CS; Herz M;
Diabet Med; 2004 Aug; 21(8):859-66. PubMed ID: 15270789
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, tolerability and safety of nateglinide in combination with metformin. Results from a study under general practice conditions.
Schatz H; Schoppel K; Lehwalder D; Schandry R
Exp Clin Endocrinol Diabetes; 2003 Aug; 111(5):262-6. PubMed ID: 12951631
[TBL] [Abstract][Full Text] [Related]
19. Three-month treatment with pioglitazone reduces circulating levels of S100A8/A9 (MRP8/14) complex, a biomarker of inflammation, without changes in body mass index, in type 2 diabetics with abdominal obesity.
Nakatsuji H; Kishida K; Funahashi T; Shimomura I;
Diabetes Res Clin Pract; 2012 Mar; 95(3):e58-60. PubMed ID: 22154375
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of pioglitazone in type 2 diabetes in the Indian patients: Results of an observational study.
Balaji V
Indian J Endocrinol Metab; 2013 Jul; 17(4):709-15. PubMed ID: 23961491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
